Advancing Human-Relevant Systems to Reduce Reliance on Animal Models
Integrated • Predictive • Translational
Accelerating Smarter, More Human-Relevant Medicine
​
Our Story
​
A Vision Born in the Lab
NAMina Bio was founded on a simple conviction in July 2025: the future of medicine must be both scientifically advanced and ethically responsible.
After years of studying cancer molecular biology and therapeutic resistance in 3D in vitro systems, our founder, Dr Paola Dama, learned the limits of traditional animal testing and the vast potential of human-based models.
​
From Research to Revolution
With deep expertise in 3D models, organoids, organ-on-chip platforms, and multi-omics analysis, our team and partners have spent decades perfecting models that truly mirror human biology.
These systems reveal how drugs behave in the body far more accurately than animal experiments ever could: accelerating discovery, improving safety, and reducing cost.
​
Science with a Soul
NAMina Bio’s name reflects its mission:
NAM for New Approach Methodologies, and ina, from anima: the soul.
For Dr Dama, a lifelong wild-animal rescuer, every life has value. Her compassion for living creatures inspired a company that proves cutting-edge science and empathy can coexist.
​
Aligned with a New Era
Our work aligns with the FDA Modernization Act 2.0, which officially recognizes non-animal methods for drug testing.
At last, science and regulation are moving together, opening the door to a future where human-relevant models replace animal experiments.
​
A Dream Realized
NAMina Bio stands at the crossroads of innovation and conscience.
We unite technology, AI-driven analytics, and human-based biology to create a more predictive, humane path for drug discovery.
What began as a dream is now a movement, one that mirrors the momentum of history itself.
​
Healing Without Harm
Our story is more than a company origin; it’s a commitment:
-
to heal without harm,
-
to innovate without cruelty,
-
and to shape a world where compassion drives discovery.
​
Paola Dama, PhD
​
Born in Naples, Italy, Paola Dama is a molecular oncology scientist and translational innovator with over 20 years of experience in cancer research, gene therapy, immonotherapy, and human-relevant preclinical science. Dr. Dama serves as Founder & CEO of NAMina Bio, leading strategic scientific integration across translational partners, AI platforms, and organ-on-chip technologies.
She holds a Master’s Degree in Cellular Biology and a Doctorate in Molecular Oncology. Throughout her career, she has worked at the intersection of rigorous biology, ethical innovation, and real-world clinical impact, advancing research strategies that bridge laboratory discovery with patient-centered applications.
Beyond the laboratory, Paola is deeply committed to scientific responsibility, transparency, and public trust. She serves on the editorial boards of Cancer Gene Therapy (Nature Portfolio) and Frontiers in Transplantation, Cell and Stem Cell, contributing to the integrity and advancement of biomedical research.
She is the founder and former president of Task Force Pandora (Italy), a scientific advocacy initiative dedicated to addressing environmental contamination and misinformation in the Campania region through education, public debate, and community engagement.
Paola is also the author of Falsa Equivalenza, a book exploring scientific misinformation and false balance in public discourse.
An international STEM advocate, she has received recognition for her social and scientific commitment, reflecting her lifelong mission to align innovation with ethical responsibility and societal impact.